I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 513 652 905 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O.

Alexandria, VA 22313-1450, on the date shown below.

ted: August 18, 2005

Patent Docket No. 500862001500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of: Dominique P. BRIDON

Serial No.: 09/657,336

Filing Date: September 7, 2000

For: LONG LASTING FUSION PEPTIDE

INHIBITORS OF VIRAL INFECTION

Examiner: J. Parkin

Group Art Unit: 1648

SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

With the application; accordingly, no fee or separate requirements are required.
Before the mailing of a first Office Action after the filing of a Request for Continued
Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
(e)(1) has been provided.
Within three months of the application filing date or before mailing of a first Office Action
on the merits; accordingly, no fee or separate requirements are required. However, if
applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

sf-1959648

\boxtimes	After	er receipt of a first Office Action on the merits but before mailing of a final Office			
	Actio	on or Notice of Allowance.			
		A fee is required. A check in the amount of is enclosed.			
	\boxtimes	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached			
	to this submission in duplicate.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is			
		believed to be due.			
	After mailing of a final Office Action or Notice of Allowance, but before payment of the				
	issue fee.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the			
		amount of is enclosed.			
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal			
		form (PTO/SB/17 is attached to this submission in duplicate.)			
	A	applicants would appreciate the Examiner initialing and returning the Form			

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 500862001500.

Dated: August 18, 2005

Respectfully submitted,

Michael R. Ward

Registration No.: 38,651

MORRISON & FOERSTER LLP

(415) 268-6237



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known			
Application Number	09/657,336		
Filing Date	September 7, 2000		
First Named Inventor	Dominique P. BRIDON		
Art Unit	Not Yet Assigned		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	500862001500		


U.S. PATENT DOCUMENTS					
Examiner	C:4-	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No. ¹	Number-Kind Code ² (if known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	1.	US-4,652,629	03-24-1987	Patrick et al.	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
0						

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2.	ARCHAKOV, Alexander I. et al. (2003) "Protein-Protein Interactions as	
		a Target for Drugs in Proteomics," Proteomics, 3: 380-391	
	3.	DAVIES, David R. et al. (Jan. 1996) "Interactions of Protein Antigens	
		with Antibodies," Proc. Natl. Acad. Sci. USA, 93: 7-12	
"	4.	JIANG, Shibo et al. (2002) "Peptide and Non-peptide HIV Fusion	
		Inhibitors," Current Pharmaceutical Design, 8: 563-580	<u> </u>
	5.	JONES, Susan et al. (Jan. 1996) "Principles of Protein-Protein	
		Interactions," Proc. Natl. Acad. Sci. USA, 93: 13-20	
	6.	KWONG, Peter D. et al. (Feb. 2000) "Oligomeric Modeling and	
		Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human	
		Immunodeficiency Virus," Journal of Virology, 74(4): 1961-1972	
	7.	KUIKEN, C. et al. ed. <u>HIV Sequence Compendium 2001</u> , Theoretical	
		Biology and Biophysics Group, Los Alamos National Laboratory, 2002: 288-289	
	8.	LAWLESS, Mary K. et al. (1996) "HIV-1 Membrane Fusion	
		Mechanism: Structural Studies of the Interactions between	
,		Biologically-Active Peptides from gp41," Biochemistry, 35: 13697-	
	<u> </u>	13708	
	9.	SANDERS, Rogier W. et al. (Sep. 2002) "Stabilization of the Soluble,	
		Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of	
		Human Immunodeficiency Virus Type 1," Journal of Virology, 76(17) 8875-8889	

Examiner	Date
Signature	Considered



10.	Domains of gp120 from Human Immunodeficiency Virus Type 1: La of Correlation with Viral Phenotype," Journal of Virology, 69(4): 2705 2715	
11.	YANG, Xinzhen et al. (May 2000) "Modifications that Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution," Journal of Virology, 74(10): 4746-4754	

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.